A Breakthrough in Periodontal Treatment

ProEncia Biotechnology is redefining periodontal care by developing a new class of highly effective therapeutic treatments. Our groundbreaking technology delivers a safe and innovative solution for patients suffering from gum disease.

An Under-Treated Condition

Periodontal disease is the most common disease in the world.

According to the World Health Organization (WHO), over 1 billion people suffer from severe cases globally. In the United States alone, over 50% of adults suffer from some level of periodontal disease.

Symptoms are serious. These can include severe pain, chronic halitosis, temperature sensitivity, and irreversible tissue and bone loss. Emerging research has also linked periodontal disease with enhanced risk of Alzheimer's, dementia, heart disease, lung disease, poorer COVID outcomes and immune system compromise, and other comorbidities.

The ProEncia Approach

For decades, periodontal care has focused on treating isolated indicators
(such as gum pain or halitosis) while leaving the underlying condition largely untreated.

ProEncia takes a holistic approach, aiming to treat the disease and underlying chronic state rather than the symptoms alone. It is underpinned by a deep knowledge of chronic inflammatory disease and our team’s 30+ years of groundbreaking pharmaceutical discovery and research.

We aim to commercialize a treatment that is safer and more effective than any currently available on the market.